Clinical management of patients receiving cell-based immunoregulatory therapy.
| Autor: | Hutchinson JA; Department of Surgery, Experimental Surgery Division, University Hospital Regensburg, Regensburg, Germany., Ahrens N, Riquelme P, Walter L, Gruber M, Böger CA, Farkas S, Scherer MN, Broichhausen C, Bein T, Schlitt HJ, Fändrich F, Banas B, Geissler EK |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Transfusion [Transfusion] 2014 Sep; Vol. 54 (9), pp. 2336-43. Date of Electronic Publication: 2014 Apr 04. |
| DOI: | 10.1111/trf.12641 |
| Abstrakt: | Administering immunoregulatory cells as medicinal agents is a revolutionary approach to the treatment of immunologically mediated diseases. Isolating, propagating, and modifying cells before applying them to patients allows complementation of specific cellular functions, which opens astonishing new possibilities for gain-of-function antigen-specific treatments in autoimmunity, chronic inflammatory disorders, and transplantation. This critical review presents a systematic assessment of the potential clinical risks posed by cell-based immunotherapy, focusing on treatment of renal transplant recipients with regulatory macrophages as a concrete example. (© 2014 AABB.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Plný text